{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T14:40:46Z","timestamp":1720276846006},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jcv.2015.07.311","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T19:24:27Z","timestamp":1438197867000},"page":"120-127","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure"],"prefix":"10.1016","volume":"70","author":[{"given":"Kristof","family":"Theys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Abecasis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Libin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perp\u00e9tua","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Cabanas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo J.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.07.311_bib0005","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http:\/\/aidsinfo.nih.gov\/ContentFiles\/Adultand AdolescentGL.pdf [Accessed at January 10th 2015]."},{"key":"10.1016\/j.jcv.2015.07.311_bib0010","unstructured":"European AIDS Clinical Society (EACS) Guidelines 7.1 Available at http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html [Accessed at January 10th 2015]."},{"key":"10.1016\/j.jcv.2015.07.311_bib0015","unstructured":"Tivicay US. prescribing information. (August 2013). http:\/\/www.accessdata.fda.gov\/ drugsatfda_docs\/label\/ 2013\/204790lbl.pdf. [Accessed June 2014]."},{"key":"10.1016\/j.jcv.2015.07.311_bib0020","unstructured":"Tivicay -EMEA\/H\/C\/002753\u2013EPAR product information. (February 2014) Annex I: Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002753\/WC500160680 pdf. Accessed June 2014."},{"key":"10.1016\/j.jcv.2015.07.311_bib0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcv.2015.07.311_bib0030","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"Canducci","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.07.311_bib0035","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/jac\/dkt220","article-title":"In vitro phenotypes to elvitgravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir","volume":"68","author":"Canducci","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2015.07.311_bib0040","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.07.311_bib0045","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.07.311_bib0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.07.311_bib0055","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2878","article-title":"Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING -4, a randomized study","author":"Akil","year":"2014","journal-title":"Antivir Ther."},{"key":"10.1016\/j.jcv.2015.07.311_bib0060","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcv.2015.07.311_bib0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0b013e328323da60","article-title":"Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies","volume":"23","author":"Canducci","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2015.07.311_bib0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkp153","article-title":"Evolution of raltegravir resistance during therapy","volume":"64","author":"Sichtig","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcv.2015.07.311_bib0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","article-title":"Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients\u2013impact of HIV subtypes and prior raltegravir experience","volume":"90","author":"Garrido","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2015.07.311_bib0080","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/jac\/dkr389","article-title":"The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype","volume":"66","author":"Malet","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2015.07.311_bib0085","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2015.07.311_bib0090","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1128\/AAC.01835-13","article-title":"Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase","volume":"57","author":"Quashie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.07.311_bib0095","article-title":"Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N 155H and multiclass drug resistance","author":"Hardy","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2015.07.311_bib0100","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors","volume":"69","author":"Malet","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2015.07.311_bib0105","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/bioinformatics\/btt162","article-title":"RegaDB: community-driven data management and analysis for infectious diseases","volume":"29","author":"Libin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcv.2015.07.311_bib0110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcv.2015.07.311_bib0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","article-title":"Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools","volume":"19","author":"Pineda-Pe\u00f1a","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.jcv.2015.07.311_bib0120","first-page":"642","article-title":"Update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jcv.2015.07.311_bib0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00002030-200203290-00008","article-title":"Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial","volume":"16","author":"Meynard","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2015.07.311_bib0130","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2015.07.311_bib0135","doi-asserted-by":"crossref","first-page":"e61436","DOI":"10.1371\/journal.pone.0061436","article-title":"Clinical evaluation of Rega : an updated genotypic interpretation system that significantly predicts HIV-therapy response","volume":"8","author":"Vercauteren","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcv.2015.07.311_bib0140","unstructured":"ISENTRESS US. prescribing information. (February 2011). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022145s018lbl.pdf."},{"key":"10.1016\/j.jcv.2015.07.311_bib0145","unstructured":"STRIBILD US. prescribing information. (August 2012). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203100s000lbl.pdf."},{"key":"10.1016\/j.jcv.2015.07.311_bib0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1742-4690-5-74","article-title":"Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors","volume":"5","author":"Rhee","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.jcv.2015.07.311_bib0155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2015.07.311_bib0160","unstructured":"R Development Core Team: R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2011."},{"key":"10.1016\/j.jcv.2015.07.311_bib0165","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jcv.2015.07.311_bib0170","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 4results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.07.311_bib0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1743-422X-8-149","article-title":"HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients","volume":"8","author":"Piralla","year":"2011","journal-title":"Virology Journal"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215006125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215006125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T11:50:14Z","timestamp":1537444214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215006125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":35,"alternative-id":["S1386653215006125"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.07.311","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.07.311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}